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Edited by Jesus AvilaAbstract The protein kinase transforming-growth-factor-b-
activated kinase-1 (TAK1) is a key regulator in the pro-inﬂam-
matory signaling pathway and is activated by tumor necrosis
factor-a, interleukin-1 (IL-1) and lipopolysaccharide (LPS).
We describe the identiﬁcation of TAK1 as a client protein of
the 90 kDa heat-shock protein (Hsp90)/cell division cycle protein
37 (Cdc37) chaperones. However, Hsp90 is not required for the
activation of TAK1 as short exposure to the Hsp90 inhibitor,
17-(allylamino)-17-demethoxygeldanamycin (17-AAG) did not
aﬀect its activation by LPS or IL-1. Prolonged treatment of cells
with 17-AAG inhibits Hsp90 and downregulates TAK1. Our re-
sults suggest that Hsp90 is required for the folding and stability
of TAK1 but is displaced and no longer required when TAK1 is
complexed to TAK1-binding protein-1 (TAB1).
Structured summary:
MINT-6797182:
TAK1 (uniprotkb:O43318-2) physically interacts (MI:0218)
with CDC37 (uniprotkb:Q16543) and HSP90 (uni-
protkb:P07900) by anti bait coimmunoprecipitation (MI:0006)
MINT-6797194:
TAK1 (uniprotkb:O43318-2) physically interacts (MI:0218)
with TAB1 (uniprotkb:Q15750), HSP90 (uniprotkb:P07900)
and CDC37 (uniprotkb:Q16543) by anti bait coimmunoprecip-
itation (MI:0006)
MINT-6797248:
TAK1 (uniprotkb:Q62073) physically interacts (MI:0218) with
HSP90 (uniprotkb:P07901), CDC37 (uniprotkb:Q61081),
TAB2 (uniprotkb:Q99K90) and TAB1 (uniprotkb:Q8CF89)
by anti bait coimmunoprecipitation (MI:0006)Abbreviations: 17-AAG, 17-(allylamino)-17-demethoxygeldanamycin;
Cdc37, cell division cycle protein 37; CUE, coupling of ubiquitin
conjugation to endoplasmic reticulum degradation; DMEM, Dul-
beccos modiﬁed Eagles medium; ELISA, enzyme-linked immunosor-
bent assay; FCS, foetal-calf serum; GST, glutathione S-transferase;
HA, haemagglutinin; HEK293, human embryonic kidney 293 cells;
Hsp90, 90 kDa heat-shock protein; IjB, inhibitor of NF-jB; IKK,
inhibitor of nuclear factor jB kinase; IL, interleukin; IRAK, interleu-
kin-1 receptor-associated kinase; JNK, c-Jun N-terminal kinase; LPS,
lipopolysaccharide; MAPK, mitogen-activated protein kinase; MKK,
MAP kinase kinase; MyD88,myeloid diﬀerentiation factor 88; NF-jB,
nuclear factor jB; RIP, receptor-interacting protein; TAB, TAK1-
binding protein; TAK1, transforming-growth-factor-b-activated
kinase-1; TNF, tumor necrosis factor; TRADD, TNF receptor-
associated death domain; TRAF, TNF-receptor-associated factor;
Ubc13, ubiquitin-conjugating enzyme 13; Uev1A, ubiquitin E2
variant 1a
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TAK1 (uniprotkb:O43318-2) physically interacts (MI:0218)
with TAB2 (uniprotkb:Q9NYJ8), CDC37 (uniprotkb:Q16543),
HSP90 (uniprotkb:P07900) and TAB1 (uniprotkb:Q15750) by
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Transforming-growth-factor-b-activated kinase-1 (TAK1) is
a protein kinase that plays a key role in the pro-inﬂammatory
pathway [1]. It activates the c-Jun N-terminal kinase (JNK),
NFjB and p38 pathways when stimulated with the cytokines
interleukin-1 (IL-1) and tumor necrosis factor-a (TNFa) or
lipopolysaccharide (LPS), a component of the gram negative
bacterial cell wall. In cells, TAK1 can exist as the catalytic
component of two diﬀerent complexes TAK1–TAB1–TAB2
or TAK1–TAB1–TAB3 [2]. TAK1-binding protein-1 (TAB1)
is required for TAK1 activity and several groups have shown
that TAK1 is inactive in cells deﬁcient for TAB1 [3–5].
TAB2 and TAB3 are adapter proteins containing ubiquitin
binding domains which are required for the activation of
TAK1 [2,6–9].
Binding of LPS or IL-1 to their receptors leads to the recruit-
ment of an adapter protein called myeloid diﬀerentiation fac-
tor 88 (MyD88) and the sequential phosphorylation and
activation of interleukin-1 receptor-associated kinase 4
(IRAK4) and IRAK1 [reviewed in 10]. The hyperphosphoryl-
ated IRAK1 is then released from the membrane complex and
stimulates the synthesis of K-63 polyubiquitin chains by TNF-
receptor-associated factor 6 (TRAF6)/ubiquitin E2 variant 1a
(Uev1A)/ubiquitin-conjugating enzyme 13 (Ubc13) [11]. The
K-63 linked polyubiquitin chains activates TAK1 by binding
to the coupling of ubiquitin conjugation to endoplasmic retic-
ulum degradation (CUE) domain of the associated proteins
TAB2 or TAB3 [8]. Ligation of TNFa to the TNFR1 receptor
leads to the binding of TNF receptor-associated death domainblished by Elsevier B.V. All rights reserved.
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and TRAF5 followed by ubiquitination of receptor-interacting
protein (RIP) 1. The protein kinase RIP1 is modiﬁed with K-
63 linked polyubiquitin chains which allow it to bind and acti-
vate the TAK1 complex via TAB2 and TAB3 [reviewed in 12].
Once TAK1 is activated, it can lead to the activation of the
inhibitor of nuclear factor jB kinase (IKK) complex and sub-
sequently NFjB. TAK1 can also activate the p38a and JNK
pathways via phosphorylation of MAP kinase kinase (MKK)
3/6 and MKK4/7, respectively [13,14]. Cells which are deﬁcient
in TAK1 are unable to activate NFjB and JNK when stimu-
lated by IL-1 while signaling through the p38a pathway is re-
duced [1]. Signaling pathways downstream of TNFa are also
severely impaired in TAK1 deﬁcient cells [1,15]. These results
demonstrate the importance of TAK1 in the pro-inﬂammatory
signaling pathways. In order to further understand the regula-
tion of TAK1, we have sought to identify proteins that interact
with and regulate TAK1. In this paper we have identiﬁed
90 kDa heat-shock protein (Hsp90) and cell division cycle pro-
tein 37 (Cdc37) as proteins that are bound to endogenous
TAK1 but are not detectable when TAK1 is bound to TAB1.2. Materials and methods
2.1. Reagents and chemicals
17-(Allylamino)-17-demethoxygeldanamycin (17-AAG), geldanamy-
cin and radicicol were from AG Scientiﬁc (San Diego, USA),
SB203580 was from Calbiochem (La Jolla, USA), PD98059 was from
Promega (Madison, USA). LPS was purchased from Sigma (St Louis,
USA). All other chemicals were purchased from either Merck or Sig-
ma.
2.2. Buﬀers
Buﬀer A [50 mM Tris/HCl pH 7.5, 0.1 mM EGTA, 1% (w/w) Triton
X-100, 1 mM Na3VO4, 50 mM NaF, 5 mM sodium pyrophosphate,
0.27 M sucrose, 0.1% (v/v) 2-mercaptoethanol plus 1 tablet/50 ml of
EDTA free complete protease inhibitor cocktail (Roche, Germany)].
Buﬀer B [50 mM Tris/HCl pH 7.5, 0.27 M sucrose and 0.1% (v/v) 2-
mercaptoethanol].
2.3. Antibodies
TAK1, TAB1 and TAB3 antibodies have been described previously
(2) and were generously provided by Prof. Sir Philip Cohen, University
of Dundee, UK. TAB2, IRAK1, Cdc37, Hsp90 and actin antibodies
were purchased from Santa Cruz (Santa Cruz, USA). Antibodies rec-
ognizing the phosphorylated form of p38a [pThr180/pTyr182], phos-
phorylated form of inhibitor of NF-jB (IjB) [pSer32], total p38a,
IjB and IRAK4 were purchased from Cell Signaling (Beverly,
USA). Antibody recognizing the phosphorylated forms of JNK1 and
2 [pThr183/pTyr185] was from BioSource (Carlsbad, USA).2.4. DNA plasmids
The following constructs were used in this study: pEBG2T–TAB1,
pEBG2T–TAK1, pEBG2T–TAK1 [345–579], pEBG2T–TAK1 [18–
370], pEF6–TAB2–HA, pEF6–TAB3–HA, pCMV5–TAK1-myc and
pCMV5–TAB1–FLAG. pSUPER–GFP–TAK1 [88] and pSUPER–
GFP–TAB1 [218] were constructed by cloning the sequences 5 0-[ccga-
gatcgactacaaggagattcaagag atctccttgtagtcgatctcttttt]-30; 5 0-[ccgcaacc-
gagtgacc aacttttcaagagaaagttggtcactcggttgcttttt]-3 0, respectively, into
the BglII/HindIII site of pSUPER–GFP (Oligoengine, Seattle, USA).2.5. Tissue culture and cell stimulation
Human embryonic kidney 293 cells (HEK293) and HeLa cells were
cultured in Dulbeccos modiﬁed Eagles medium (DMEM) supple-
mented with 10% foetal-calf serum (FCS) (Hyclone, Logan, USA)
and antibiotics (100 units/ml penicillin and 100 lg/ml streptomycin).
The cells were incubated at 37 C with a humidiﬁed atmosphere of5% CO2. 16 h prior to stimulation with TNFa and IL-1b, HeLa cells
were incubated in DMEM plus antibiotics but without FCS. At the
same time, the cells were incubated with 10 lM 17-AAG dissolved in
DMSO or DMSO alone. After 16 h, the cells were stimulated with
50 ng/ml of either TNFa or IL-1b. Cells were then harvested at diﬀer-
ent timepoints with buﬀer A and used immediately or stored at 20 C
until required. RAW 264.7 macrophages were grown using the same
conditions as HEK293 and HeLa cells except the FCS used was heat
inactivated. At 1 or 16 h prior to stimulation with 100 ng/ml LPS, cells
were treated with the following compounds dissolved in DMSO, 17-
AAG, geldanamycin, radicicol, SB203580 or PD98059. Cells and med-
ia were collected at the indicated timepoints and used immediately or
stored at 20 C until required. TNFa secreted by the macrophages
into the media was measured by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturers instructions (Bender Med-
Systems, Austria). Media was diluted so that the measured concentra-
tion of TNFa was linear with respect to the absorbance in the ELISA.
HEK293 cells were transfected according to a modiﬁed calcium phos-
phate precipitation [25].
2.6. Glutathione S-transferase (GST) pulldown and immunoprecipitation
Protein lysates from cells were centrifuged at 14000 · g for 5 min at
4 C and the insoluble debris discarded. 1 mg of the protein lysate
supernatant was incubated with 10 ll of glutathione–sepharose beads
(GE Healthcare, Little Chalfont, Bucks, UK) for 1 h at 4 C. The pro-
tein bound to the glutathione–sepharose beads was separated from the
supernatant by centrifugation, washed twice with 1 ml of buﬀer A con-
taining 0.5 M NaCl and twice with 1 ml buﬀer B. Immunoprecipita-
tions were carried out using the same method except glutathione–
sepharose beads were substituted with 2 lg of antibody coupled to
10 ll of protein-G-agarose beads.3. Results
3.1. TAK1 but not TAB1, TAB2 or TAB3 interacts with Hsp90
While investigating the regulation of TAK1, we observed on
SDS–PAGE an unknown protein of approximately 90 kDa in
size which co-puriﬁed with overexpressed GST–TAK1 from
HEK293. Since Hsp90 has been shown to bind to many pro-
tein kinases, we investigated further to see whether the un-
known 90 kDa protein bound to TAK1 is indeed Hsp90.
When aﬃnity puriﬁed anti-TAK1 antibody was used to immu-
noprecipitate endogenous TAK1 from HEK293 cells, the pres-
ence of Hsp90 was detected by western blotting with anti-
Hsp90 antibody (Fig. 1A). Cdc37, a known binding partner
of Hsp90 that targets it to kinase clients was also detected as
co-precipitating with TAK1. As control, a non-speciﬁc sheep
antibody was used in a separate immunoprecipitation and nei-
ther Hsp90 nor Cdc37 were detected. This shows that TAK1 is
bound to Hsp90 and Cdc37 in cells. Since TAK1 exists in cells
in two diﬀerent complexes consisting of TAK1–TAB1–TAB2
or TAK1–TAB1–TAB3, we examined which of the four pro-
teins (TAK1, TAB1, TAB2 or TAB3) contain the binding site
for Hsp90. Exogenous GST–TAK1, GST–TAK1 [18–370],
GST–TAK1 [345–579], GST–TAB1 or GST–TAK1 [345–
579] co-expressed with TAB2–HA or TAB3–HA were puriﬁed
from HEK293 cells and the presence of Hsp90 and Cdc37
examined (Fig. 1B). As TAB2 and TAB3 expressed poorly
on their own they had to be co-expressed with GST–TAK1
[345–579] to enhance their expression. This observation has
also been reported by others [5]. Endogenous Hsp90 and
Cdc37 were found to bind only to GST–TAK1 and the kinase
domain mutant GST–TAK1 [18–370] but not to GST–TAB1,
GST–TAK1 [345–579], or GST–TAK1 [345–579] complexed
to TAB2 or TAB3. We then examined whether the presence
of TAB1, TAB2 and TAB3 aﬀects binding of Hsp90 or
Fig. 1. TAK1 is associated with Hsp90 and Cdc37 in cells. (A) TAK1 was immunoprecipitated from HEK293 protein lysates using a TAK1 speciﬁc
sheep antibody (lane 2) or control pre-immune antibody (lane 1) pre-coupled to Protein-G agarose. The immune complex was washed extensively,
denatured in SDS sample buﬀer and analyzed by western blotting with antibodies speciﬁc for Hsp90, Cdc37 or TAK1. (B and C) HEK293 cells were
transfected with DNA plasmids encoding the proteins indicated. The cells were harvested and the proteins aﬃnity puriﬁed with glutathione–
sepharose. Puriﬁed proteins were subjected to SDS–PAGE and transferred to nitrocellulose. Endogenous Hsp90 and Cdc37 bound to the puriﬁed
proteins and the expression of GST- and HA-tagged proteins in the pulldown (B) protein lysates (C) were veriﬁed using speciﬁc antibodies. (D)
HEK293 cells were transfected with shRNA vector targeting TAB1 or the empty control vector. Endogenous TAK1 was immunoprecipitated using
speciﬁc antibody and the levels of TAK1 and bound Hsp90, Cdc37 and TAB1 probed with speciﬁc antibodies. Total TAB1, TAB2 and TAB3 in the
protein lysates were immunoprecipitated and subjected to western blotting with the indicated antibodies.
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TAK1 for Hsp90 and Cdc37 (Fig. 1C). However, TAB2 and
TAB3 did not aﬀect the interaction between TAK1 and endo-
genous Hsp90 or Cdc37.
When we knocked down endogenous TAB1 with RNAi, the
level of endogenous TAK1 protein was not aﬀected but bind-ing to Hsp90 and Cdc37 increased dramatically (Fig. 1D).
Thus in the absence of TAB1 or when TAB1 is limiting,
TAK1 can be stabilized by the binding of Hsp90. This is
consistent with the similar levels of TAK1 that is observed in
wild type and TAB1 knockout mouse embryonic ﬁbroblasts
[4].
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complexes were overexpressed in HEK293 cells and puriﬁed
by a histidine tag on TAB1, we were unable to detect endoge-
nous Hsp90 and Cdc37 in both complexes (results not shown).
This shows that when TAK1 is in complex with TAB1–TAB2
or TAB1–TAB3, binding to Hsp90 is not required. Our results
suggest that Hsp90 and TAB1 can both bind to the catalytic
domain of TAK1 and binding of Hsp90 and TAB1 is mutually
exclusive.
3.2. Hsp90 is required for TAK1 polypeptide stability
We examined whether inhibition of Hsp90 by 17-AAG af-
fects the stability of TAK1 and its associated proteins TAB1,
TAB2 and TAB3. HEK293 cells were treated for 16 h with
10 lM 17-AAG or DMSO control (Fig. 2A). Because our anti-
bodies were not sensitive enough to detect endogenous TAK1,
TAB1, TAB2 and TAB3 in protein lysates, the proteins were
ﬁrst immunoprecipitated using protein speciﬁc antibodies
and then imunoblotted. In cells treated with 17-AAG, a dra-
matic decrease in the level of TAK1 was detected. However,
levels of TAB1, TAB2 and TAB3 were unaﬀected by 17-
AAG treatment. Similar results were observed when cells were
treated with radicicol, an inhibitor of Hsp90 that is structurally
diﬀerent from 17-AAG (results not shown). This suggests that
Hsp90 directly aﬀects the stability of TAK1 but not TAB1,
TAB2 and TAB3. Similarly, when the TAK1 protein was
knocked down by RNAi, levels of TAB1, TAB2 and TAB3
were not signiﬁcantly aﬀected indicating that their stability is
not dependent on TAK1 protein level.
When TAB1 levels are reduced, the proportion of TAK1–
Hsp90 to TAK1–TAB1 complexes increases (Fig. 1D). There-
fore, we examined whether TAK1 is degraded more quickly
upon Hsp90 inhibition by 17-AAG when TAB1 levels are re-
duced (Fig. 2D). HEK293 cells were transfected with RNAi
targeting TAB1 or RNAi control. In cells expressing the RNAi
control, TAK1 level was not reduced at 3 h post treatment
with 17-AAG. However, in cells expressing the TAB1 RNAi,
the 17-AAG induced reduction in TAK1 was apparent within
3 h. Levels of TAK1 were further decreased in both TAB1
knockdown and control cells at 16 h. These results suggests
that 17-AAG preferentially downregulates populations of
TAK1 complexed to Hsp90.
Other protein kinases in the pro-inﬂammatory pathway have
been reported to bind to Hsp90. To further validate our system
and to show that 17-AAG does not downregulate protein ki-
nase levels non-speciﬁcally, we probed for endogenous IRAK1
and IRAK4 protein which function upstream of TAK1 as con-
trols (Fig. 2B). In both HeLa and HEK293 cells, prolonged
exposure to 17-AAG downregulates IRAK1 but not IRAK4
as also reported previously [20]. The time and concentration
eﬀects of 17-AAG on TAK1 and IRAK1 are shown in
Fig. 2C. 17-AAG (10 lM) caused a decrease in TAK1 levels
initially at 4 h while a decrease in IRAK1 levels was not de-
tected until 8 h to 12 h. Both IRAK1 and TAK1 levels were
unaﬀected at concentrations below 2.5 lM.3.3. IL-1b and LPS stimulation does not aﬀect Hsp90 binding to
TAK1
We examined whether IL-1b or LPS stimulation aﬀects the
amount of Hsp90 that is bound to TAK1. When cells were
stimulated with IL-1b (Fig. 2E) or LPS (Fig. 2F), the bindingof Hsp90, Cdc37, TAB1 and TAB2 to TAK1 was unchanged
throughout the course of stimulation. Unexpectedly, the acti-
vation of TAK1 shows biphasic activation characteristics with
maximal activation at 15 mins. A prolonged period of deacti-
vation was followed by modest reactivation of TAK1 at 2 h
after stimulation. The biphasic activation of TAK1 mirrors
the activation of p38a.
To explore whether inhibition of Hsp90 by 17-AAG can
aﬀect TAK1 activation without destabilizing TAK1, cells were
exposed to 17-AAG for only 1 h before stimulation with IL-1b
or LPS. We found that Hsp90 and Cdc37 binding to TAK1
were decreased but the activation of TAK1 was not aﬀected
again suggesting that Hsp90 or Cdc37 are not required for
TAK1 activity. Similarly, p38a activation was not aﬀected by
short exposure to 17-AAG. Dissociation of Hsp90/Cdc37 from
TAK1 did not have any eﬀect on the amount of TAB1 or
TAB2 bound to TAK1. The absence of Hsp90 and Cdc37 in
the TAK1 immunoprecipitates from 17-AAG treated cells fur-
ther indicates the TAK1 antibody used in this study do not
bind Hsp90 and Cdc37 in a non-speciﬁc manner (Fig. 2E
and F).
3.4. Prolonged incubation with 17-AAG inhibits signaling by
IL-1b, TNFa and LPS
Since TAK1 is a key mediator in the IL-1b, TNFa and
LPS signaling pathways, we investigated the eﬀect of Hsp90
inhibition by 17-AAG on the activation of NFjB, p38a
and JNK, which function downstream of TAK1. When HeLa
cells were stimulated with IL-1b (Fig. 3A), phosphorylation
on Thr180/Tyr182 of p38a can be observed from 5 min to
20 min but pretreatment with 17-AAG caused the IL-1b acti-
vation of p38a to be drastically reduced. Activation of the
JNK pathway was observed within 5 min by IL-1b and
peaked at 20 min. Cells exposed to 17-AAG did not exhibit
any activation of the JNK pathway. Rapid phosphorylation
on Ser32 of IjB was seen at 5 min after IL-1b stimulation.
In 17-AAG treated cells, phosphorylation was decreased sig-
niﬁcantly and prolonged till 10 min. However, when total
level of IjB was examined, protein level of IjB was degraded
at 5 min and did not reappear until 30 min after stimulation.
In 17-AAG treated cells, the total IjB levels were readily ob-
served at all time points and degradation of IjB was not
seen.
Similar results were observed in TNFa stimulated HeLa
(Fig. 3B) and LPS stimulated RAW macrophages (Fig. 3C).
These results show that 17-AAG is a potent inhibitor of IL-
1b, TNFa and LPS signaling by reducing markedly the activa-
tion of the NFjB, p38a and JNK signaling pathways.
Although decreases in TAK1 levels were similar in cells trea-
ted with 17-AAG or knocked down with RNAi targeting
TAK1 (Fig. 2A), a far greater reduction in signaling of the
NFjB, p38a and JNK signaling pathways was evident in 17-
AAG treated cells. This suggests that in addition to TAK1,
17-AAG may also downregulate other components of the
IL-1b, TNFa and LPS signaling pathways, for example
IRAK1 (Fig. 2B).3.5. Inhibition of Hsp90 in macrophages abrogates LPS
signaling and TNFa production
Since 17-AAG inhibits the activation of NFjB, p38a and
JNK in response to LPS stimulation, we examined whether
Fig. 2. Hsp90 is required for TAK1 stability but not for its activation. (A) HEK293 cells were treated with 10 lM 17-AAG (lanes 3 and 4), DMSO
(lanes 1 and 2), transfected with shRNA vector targeting TAK1 (lanes 7 and 8) or empty plasmid vector (lanes 5 and 6). The cells were harvested and
immunoprecipitation carried out using anti-TAK1, TAB1, TAB2 or TAB3 antibodies conjugated to Protein-G-agarose. After washing, the
immunoprecipitates were denatured in SDS sample buﬀer and analyzed for the presence of TAK1, TAB1, TAB2 and TAB3 by immunoblotting.
Protein lysate was probed with anti-actin antibody as loading control. (B) HEK293 or HeLa cells were treated with or without 17-AAG for 16 h and
the protein lysates were probed for endogenous IRAK1, IRAK4 and actin with speciﬁc antibodies. (C) HEK293 cells were treated with 17-AAG
(10 lM) at the times indicated or treated with diﬀerent concentrations of 17-AAG for 16 h. TAK1 was immunoprecipitated from the protein lysates
and probed for TAK1 by western blotting. Protein lysates were probed by western blotting with anti-IRAK1 antibody or used for TAK1
immunoprecipitation followed by western blotting for TAK1. (D) HEK293 cells transfected with shRNA vector targeting TAB1 or empty plasmid
vector were treated with 10 lM 17-AAG at the indicated time points. TAK1 was immunoprecipitated from the protein lysates and probed for TAK1
by western blotting. (E) HeLa or (F) RAW cells were pretreated with or without 17-AAG for 1 h, maintained in the same media and stimulated with
IL-1b or LPS, respectively, at the times indicated. Endogenous TAK1 was immunoprecipitated from the protein lysates and probed for total TAK1
and phosphorylation at Thr187. Levels of Hsp90, Cdc37, TAB1 and TAB2 which co-precipitated with TAK1 were probed with speciﬁc antibodies.
The protein lysates were probed for activation of p38a with an antibody speciﬁc for phosphorylation on Thr180/Tyr182 of p38a and total actin.
X.Y. Liu et al. / FEBS Letters 582 (2008) 4023–4031 402717-AAG can suppress TNFa secretion by RAW macrophages,
an end point used as a readout of LPS signaling. The amount
of TNFa secreted after LPS stimulation increased from the ba-
sal level of 10 to 70 ng/ml at 3 h and 110 ng/ml at 6 h. There
was a small increase in the secretion of TNFa from 6 to 12 h
(Fig. 4A).We compared the eﬃcacy of 17-AAG with other Hsp90
inhibitors such as geldanamycin and radicicol in inhibiting
LPS signaling. Protein kinase inhibitors which inhibit the clas-
sical MAP kinase pathway (PD98059) and p38a (SB203580)
were also included in this study for reference. When cells were
pretreated with the diﬀerent compounds at 16 h prior to
Fig. 2 (continued)
Fig. 3. Inhibition of Hsp90 abrogates IL-1, TNF and LPS signaling – HeLa and RAW macrophages were pre-treated with 10 lM 17-AAG or
DMSO (mock) for 16 h, maintained in the same media and stimulated with IL-1b (A), TNFa (B) or LPS (C) for the times indicated. The cells were
harvested and protein lysates were denatured in SDS and analyzed by western blotting with antibodies speciﬁc for phosphorylation on IjBa [pSer32],
p38a [pThr180/pTyr182] and JNK 1 and 2 [pThr183/pTyr185]. Total IjBa and p38a were detected using anti-IjBa and p38a antibodies. Protein
lysates were immunoblotted for total actin as loading control.
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Fig. 4. Inhibition of Hsp90 blocks TNFa secretion by macrophages. RAWmacrophages were stimulated with LPS for the indicated times (A). RAW
macrophages were pre-treated with 10 lM of the diﬀerent compounds for 1 h (B) or 16 h (C), maintained in the same media and stimulated with LPS
for 6 h. Cells were treated with diﬀerent concentrations of the compounds for 16 h, maintained in the same media and stimulated with LPS for 6 h
(D). TNFa released into the media was measured by ELISA and expressed as ng/ml in media (A) or as a percentage of TNFa secreted from control
cells treated with DMSO (B, C, D). Assays were done in triplicate and the results shown are the mean ± S.E.M. from three independent experiments.
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secretion by 50% while PD98059 reduced TNFa secretion by
20% (Fig. 4C). The Hsp90 inhibitors 17-AAG, radicicol and
geldanamycin were all equally eﬀective and reduced TNFa
secretion by up to 95%. When the cells were pretreated with
the compounds 1 h prior to LPS stimulation (black bars),
SB203580 reduced TNFa secretion by 50%, similar to the
result observed when the cells was pre-treated at 16 h
(Fig. 4B). At 1 h pre-treatment, PD98059 did not signiﬁcantly
aﬀect TNFa secretion. All the Hsp90 inhibitors reduced TNFa
secretion by only 50%, compared to a 95% reduction observed
for 16 h pre-treatment. The diﬀerence in TNFa secretion when
the cells were pretreated at 1 and 16 h is perhaps an indication
of the modes of action by the diﬀerent compounds. A longer
time is required for Hsp90 inhibition to downregulate protein
kinase activity by proteasomal degradation than that required
for the direct inhibition of p38a by protein kinase inhibitors
such as SB203580. Without LPS, none of the compounds stim-
ulated TNFa secretion (white bars).
We then compared the dose response of 17-AAG, radicicol
and SB203580 on TNFa secretion by RAW macrophages(Fig. 4D). The cells were pre-treated with the three compounds
at diﬀerent concentrations 16 h prior to stimulation with LPS.
For 17-AAG, the IC50 for TNFa secretion was 0.6 lM while
radicicol and SB203580 had IC50 of 50 nM and 0.5 lM, respec-
tively. This is consistent with reports that radicicol binds to
and inhibits Hsp90 with much higher aﬃnity than 17-AAG
[24].4. Discussion
Hsp90 is a chaperone protein that is required for the initial
folding process following polypeptide chain synthesis and for
the refolding of proteins exposed to environmental stress to
prevent aggregation [16]. The co-chaperone Cdc37 is required
to target Hsp90 to its kinase clients [16]. For some kinases,
Hsp90 is required for maturation but other kinases exhibit per-
sistent binding to Hsp90 throughout their activation/deactiva-
tion cycle [16].
For TAK1, Hsp90 is not required for its activation
since short exposure to 17-AAG had no eﬀect on Thr187
Fig. 5. Proposed mechanism of TAK1 regulation by Hsp90. (1) Hsp90 is required for the folding and stabilization of the nascent TAK1 polypeptide
chain. (2) Binding of TAB1 to TAK1 leads to the displacement of Hsp90 but TAK1 stability is maintained by TAB1. (3) 17-AAG inhibits Hsp90 and
causes dissociation of TAK1-Hsp90 complex. Stabilization of TAK1 by binding of TAB1 does not occur as levels of TAB1 are limiting. TAK1 is
unstable and undergoes proteasomal degradation. For simplicity, Cdc37, TAB2 and TAB3 are not shown, in cells TAK1 can exist as TAK1–TAB1–
TAB2 or TAK1–TAB1–TAB3 complexes.
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tion of Hsp90 would cause the dissociation of TAK1-Hsp90,
total TAK1 activity would not be aﬀected since TAK1-Hsp90
is not activated without bound TAB1. Therefore, the phos-
phorylation of Thr187 on TAK1 (Fig. 2E and F) is due entirely
to the TAK1-TAB1 pool bound to either TAB2 or TAB3. In
active TAK1 complexes which contain TAB1, Hsp90 would
no longer be present or required because both TAB1 and
Hsp90 binds to the catalytic domain of TAK1. Whether
TAB1 and Hsp90 binds to the same site within the TAK1 cat-
alytic domain is unclear. Alternatively, TAB1 may cause a con-
formational change in TAK1 that prohibits binding of Hsp90.
In cells, TAB1 is constitutively bound to TAK1 and apart
from playing a role in its activation, may also help to stabilize
TAK1. In transient expression studies, the expression of TAK1
is vastly improved by co-expression with TAB1 [unpublished
data and 23]. The mechanism by which Hsp90 in newly synthe-
sized TAK1-Hsp90 complexes is replaced by TAB1 is unclear
as neither IL-1b nor LPS stimulation altered the amount of
TAB1 or Hsp90 bound to TAK1 (Fig. 2E and F). It is possible
that the amount of TAB1 bound to TAK1 is limited by the cel-
lular amount of TAB1. Hsp90 would be displaced from TAK1
only if free TAB1 is available.
Our results suggest that Hsp90 may instead be required for
folding and maturation of the nascent TAK1 polypeptide since
activation of TAK1 does not require Hsp90 binding (Fig. 5). A
second function for Hsp90 may be to maintain the stability of
the TAK1 pool that are not yet bound to TAB1. An obvious
role for this pool of TAK1–Hsp90 is to supply TAK1 for the
formation of TAK1–TAB1 which is a stable entity. Our results
are consistent with a previous study showing a signiﬁcant por-
tion of TAK1 exists that is unbound to TAB1 [2].
When Hsp90 is inhibited, TAK1–Hsp90 dissociates and pro-
motes degradation of the free TAK1 which is unstable. How-
ever, prolonged inhibition would cause total TAK1 level to
decrease due to normal protein turnover and by preventingthe continual formation of TAK1–TAB1 complex with
TAK1 supplied from newly formed TAK1–Hsp90 (Fig. 5).
We also examined the functional consequence of Hsp90 inhi-
bition in the pro-inﬂammatory pathway. In this study we show
that three diﬀerent Hsp90 inhibitor compounds, geldanamycin,
its derivative 17-AAG and the structurally diﬀerent compound
radicicol all inhibited TNFa release after stimulation by LPS.
This points to the importance of Hsp90 to the pro-inﬂamma-
tory pathways. Previous reports have noted that radicicol and
geldanamycin have anti-inﬂammatory properties [19,20].
Although the decrease in TAK1 protein after Hsp90 inhibition
correlated well with the decrease in TNFa secretion, it has been
shown that a number of other protein kinases such as IRAK1
[20] and IKK [19,21] are also downregulated by Hsp90 inhibi-
tors while IRAK4 has been shown to be insensitive [20]. Protein
kinases in the lower tier of the mitogen-activated protein kinase
(MAPK) cascade such as p38a (Fig. 3), JNK and ERK have
been found to be unresponsive to geldanamycin [19]. It remains
to be determined which other protein kinases in the pro-inﬂam-
matory pathway are Hsp90 clients and whether they would be
aﬀected by inhibition of Hsp90.
17-AAG is currently in phase II clinical trials for the treat-
ment of cancer because it can destabilize oncogenic kinases
such as RAF1 and Her2 which require Hsp90 for their func-
tional stability [17–18]. Thus in the presence of Hsp90 inhibi-
tors these oncogenic kinases are downregulated rapidly by
the ubiquitin proteasome pathway. It may be prudent to take
into account the results presented in this and other studies
[19,20]. Since signaling in the pro-inﬂammatory pathway are
downregulated by Hsp90 inhibitors, administration of 17-
AAG may leave recipients vulnerable to infection. On the
other hand, 17-AAG and other Hsp90 inhibitors may oﬀer po-
tential for the treatment of pro-inﬂammatory diseases. A likely
scenario in which a ‘‘wholesale’’ shutdown of the pro-inﬂam-
matory pathway is required may be in acute inﬂammatory dis-
orders such as sepsis where activation of the pro-inﬂammatory
X.Y. Liu et al. / FEBS Letters 582 (2008) 4023–4031 4031pathway is upregulated uncontrollably leading to multi-organ
failure and ﬁnally death [22]. Targeting of multiple kinases by
inhibition of Hsp90 may be an eﬀective strategy for these acute
inﬂammatory conditions although prolonged administration
may have adverse eﬀects.
In summary, this report has identiﬁed TAK1 as a client pro-
tein of Hsp90. Binding of Hsp90 is required to stabilize the
nascent TAK1 polypeptide but not for its activation for which
TAB1 is required. Furthermore, we provide evidence to sup-
port previous reports that inhibition of Hsp90 abrogates
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